Choline alfoscerate sustained-release - Hyundai PharmaceuticalsAlternative Names: HT-003 - Hyundai Pharmaceuticals
Latest Information Update: 30 Mar 2015
At a glance
- Originator Hyundai Pharmaceutical
- Class Antibacterials; Antidementias; Glycerophosphates; Glycerophospholipids; Neuroprotectants; Nootropics
- Mechanism of Action Cell membrane permeability enhancers; Cholinergic receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Cognition disorders